Article Text

Download PDFPDF

137 Evidence based ESMO-ESGO-ESTRO endometrial cancer guidelines: are adequate for planning adjuvant therapy?
  1. L Fuso1,
  2. E Badellino1,
  3. M Laudani2,
  4. A Carapezzi2,
  5. G Parpinel2,
  6. F Petey2,
  7. M Barboni2,
  8. M Ribotta3,
  9. E Volpi4,
  10. A Ferrero1 and
  11. P Zola2
  1. 1Gynecology and Obstetrics, AO Ordine Mauriziano, Italy
  2. 2Department of Surgical Science, Città della Salute e della Scienza, Italy
  3. 3Pathological Anatomy, Città della Salute e della Scienza, Italy
  4. 4Gynecology and Obstetrics, Ospedale San Paolo, Italy


Introduction Endometrial cancer is the most common gynaecological cancer in developed countries. Since 2014 the ESMO-ESGO-ESTRO societies have made a great effort to outline guidelines: modulation of adjuvant therapy is even more important as advanced age and frequent co-morbidities may limit therapeutic success. It is therefore of overwhelming importance to avoid over/under-treatment.

Methods To verify the impact of treatment according to current European guidelines data over a 8 years period (01/2011 to 10/2018) were retrospectively collected in 3 Centres of the Piemonte and Valle d’Aosta Regional Cancer Network. Patients were classified according to ESMO risk class and the treatment carried out: if totally in accordance with the current guidelines, under or over-treated.

Results 723 patients were enrolled. As regards stage I endometrioid disease in accordance with the ESMO risk 237 were low risk, 94 intermediate, 132 High-intermediate and 42 high risk. Among these, they were treated in accordance with current guidelines respectively 97%, 79%, 46%, 31% of the patients with good results (98.6% censored). At the same time 3%, 21%, 14%, 33% were over-treated while 40% High-intermediate and 36% high risk undertreated. According to Cox regression survival analysis undertreatment gives a risk of death on overall survival of 9.3 (p=0.0001) compared to proper treatment but also overtreatment provide unfavourable effect OR=3.7 (p=0.05). At multivariate Cox analysis this upshot was maintained adjusting for age and ESMO risk (p=0.001).

Conclusions Patients treated in accordance with European guidelines have a good cure index, it is necessary to avoid over/under-treatment.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.